Near-infrared optical imaging of integrin αvβ3 in human tumor xenografts

Molecular Imaging

Volumn 3, Issue 4, 2004, Pages 343-351

  Wang, Wei ^a   Ke, Shi ^a   Wu, Qingping ^a   Charnsangavej, Chusilp ^a   Gurfinkel, Mikhail ^b   Gelovani, Juri G ^a   Abbruzzese, James L ^a   Sevick Muraca, Eva M ^b   Li, Chun ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Dynamic imaging; Integrins; Near infrared; Optical imaging; RGD peptide

Indexed keywords

DYNAMIC IMAGING; INTEGRINS; NEAR INFRARED; OPTICAL IMAGING; RGD PEPTIDE;

BIOMARKERS; CELLS; FLUORESCENCE; GRAFTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEDICINE; NEAR FIELD SCANNING OPTICAL MICROSCOPY; ONCOLOGY; OPTIMIZATION; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; TOMOGRAPHY; TUMORS;

DYES;

CARBOCYANINE; CY5.5 CYANINE DYE; CYCLOPEPTIDE; FLUORESCENT DYE; TUMOR MARKER; VITRONECTIN RECEPTOR;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; FLUORESCENCE MICROSCOPY; HUMAN; KAPOSI SARCOMA; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARBOCYANINES; CELL LINE, TUMOR; FLUORESCENT DYES; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; SARCOMA, KAPOSI; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 13844296431     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/1535350042973481     Document Type: Article

References (35)

1. Hynes RO (1992). Integrins: Versatility, modulation, and signaling in cell adhesion. Cell. 69:11-25.
2. Clark EA, Brugge JS (1995). Integrins and signal transduction pathways: The road taken. Science. 268:233-239.
3. Ruoslahti E, Pierschbacher MD (1987). New perspectives in cell adhesion: RGD and integrins. Science. 238:491-497.
4. van Muijen GN, Jansen KF, Cornelissen IM, Smeets DF, Beck JL, Ruiter DJ (1991). Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer. 48:85-91.
5. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992). Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest. 89:2018-2022.
6. Brooks PC, Clark RA, Cheresh DA (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264: 569-571.
7. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC (1996). A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med. 125: 369-375.
8. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK (1996). Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res. 63:169-173.
9. Eliceiri BP, Cheresh DA (1999). The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 103:1227-1230.
10. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995). Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1815-1822.
11. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995). Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1500-1502.
12. Cheresh DA (1987). Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U.S.A. 84:6471-6475.
13. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stocklin G, Schwaiger M (1999). Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med. 40:1061-1071.
14. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M (2001). Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:1781-1785.
15. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC (2002). Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 62:6146-6151.
16. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS (2004). MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 15:41-49.
17. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ (2004). Synthesis and biological evaluation of a (99 m) Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin, 43:26-32.
18. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004). Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 31:11-19.
19. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998). Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 4:623-626.
20. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM (2003). Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63:5838-5843.
21. Gurfinkel M, Ke S, Wen X, Li C, Sevick-Muraca EM (2003). Near-infrared fluorescence optical imaging and tomography. Dis Markers. 19:107-121.
22. Folli S, Westermann P, Braichotte D, Pelegrin A, Wagnieres G, van den Bergh H, Mach JP (1994). Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 54:2643-2649.
23. Ballou B, Fisher GW, Waggoner AS, Farkas DL, Reiland JM, Jaffe R, Mujumdar RB, Mujumdar SR, Hakala TR (1995). Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies. Cancer Immunol Immunother. 41:257-263.
24. Becker A, Hessenius C, Bhargava S, Grotzinger C, Licha K, Schneider-Mergener J, Wiedenmann B, Semmler W (2000). Cyanine dye labeled vasoactive intestinal peptide and somatostatin analog for optical detection of gastroenteropancreatic tumors. Ann NY Acad Sci. 921:275-278.
25. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R (2000). Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol. 35:479-485.
26. Zaheer A, Lenkinski RE, Mahmood A, Jones AG, Cantley LC, Frangioni JV (2001). In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol. 19:1148-1154.
27. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C (2003). Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 63:7870-7875.
28. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. (1999). In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 17:375-378.
29. Ntziachristos V, Weissleder R (2002). Charge-coupled-device based scanner for tomography of fluorescent near-infrared probes in turbid media. Med Phys. 29:803-809.
30. Godavarty A, Thompson AB, Roy R, Gurfinkel M, Eppstein MJ, Zhang C, Sevick-Muraca EM (2004). Diagnostic Imaging of breast cancer using fluorescence-enhanced optical tomography. J Biomed Opt. 9:488-496.
31. Ballestrem C, Hinz B, Imhof BA, Wehrle-Haller B (2001). Marching at the front and dragging behind: Differential alphaV-beta3-integrin turnover regulates focal adhesion behavior. J Cell Biol. 155:1319-1332.
32. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS (2003). Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med. 163:452-456.
33. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M (2001). Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 42:326-336.
34. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M (2004). [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 15:61-69.
35. Ke S, Wang W, Houston J, Sevick-Muraca E, Gelovani J, Li C (2004). Dual-modality optical/nuclear imaging of integrin αvβ3 in melanoma with a single imaging probe. In: Society of Molecular Imaging Annual Meeting. September 9-12, 2004, St. Louis, MO.